CN112755020A - Small molecule compound for treating osteoarthritis and application thereof - Google Patents
Small molecule compound for treating osteoarthritis and application thereof Download PDFInfo
- Publication number
- CN112755020A CN112755020A CN201910997792.7A CN201910997792A CN112755020A CN 112755020 A CN112755020 A CN 112755020A CN 201910997792 A CN201910997792 A CN 201910997792A CN 112755020 A CN112755020 A CN 112755020A
- Authority
- CN
- China
- Prior art keywords
- osteoarthritis
- alcohol
- treating osteoarthritis
- notopterygium
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 41
- -1 Small molecule compound Chemical class 0.000 title claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 15
- 238000002347 injection Methods 0.000 claims abstract description 9
- 239000007924 injection Substances 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 6
- 239000003405 delayed action preparation Substances 0.000 claims abstract 2
- 239000002674 ointment Substances 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 210000000629 knee joint Anatomy 0.000 abstract description 21
- 241001465754 Metazoa Species 0.000 abstract description 11
- 210000000845 cartilage Anatomy 0.000 abstract description 11
- 238000002474 experimental method Methods 0.000 abstract description 9
- 241000699670 Mus sp. Species 0.000 abstract description 7
- BKIACVAZUKISOR-MKMNVTDBSA-N Notopterol Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC/C=C(C)/CC(O)C=C(C)C BKIACVAZUKISOR-MKMNVTDBSA-N 0.000 abstract description 6
- 230000008961 swelling Effects 0.000 abstract description 6
- 230000007547 defect Effects 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 5
- 210000001258 synovial membrane Anatomy 0.000 abstract description 5
- 230000000451 tissue damage Effects 0.000 abstract description 3
- 231100000827 tissue damage Toxicity 0.000 abstract description 3
- BKIACVAZUKISOR-UHFFFAOYSA-N Notopterol Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CC(O)C=C(C)C BKIACVAZUKISOR-UHFFFAOYSA-N 0.000 abstract 3
- 239000002671 adjuvant Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 235000019441 ethanol Nutrition 0.000 description 28
- 238000005406 washing Methods 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 239000000243 solution Substances 0.000 description 17
- 210000001188 articular cartilage Anatomy 0.000 description 10
- 230000001926 lymphatic effect Effects 0.000 description 9
- 206010002091 Anaesthesia Diseases 0.000 description 8
- 230000037005 anaesthesia Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000002791 soaking Methods 0.000 description 8
- 210000001503 joint Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 125000003158 alcohol group Chemical group 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 210000002751 lymph Anatomy 0.000 description 6
- 239000012188 paraffin wax Substances 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 102100027995 Collagenase 3 Human genes 0.000 description 5
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 5
- 210000001365 lymphatic vessel Anatomy 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 230000002951 depilatory effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000001179 synovial fluid Anatomy 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102100037265 Podoplanin Human genes 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000003517 fume Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 101710118150 Podoplanin Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003367 anti-collagen effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000013115 immunohistochemical detection Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960004657 indocyanine green Drugs 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MPVDXIMFBOLMNW-ISLYRVAYSA-N 7-hydroxy-8-[(E)-phenyldiazenyl]naphthalene-1,3-disulfonic acid Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1\N=N\C1=CC=CC=C1 MPVDXIMFBOLMNW-ISLYRVAYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000382951 Hansenia forbesii Species 0.000 description 1
- 241000533388 Hansenia weberbaueriana Species 0.000 description 1
- 101000600766 Homo sapiens Podoplanin Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002546 full scan Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000011087 paperboard Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a small molecular compound for treating osteoarthritis, the effective component of the small molecular compound is Notopterol (Notopterol), the effective action concentration of the Notopterol is 5-25 mu M as a medicine for treating osteoarthritis. Mixing Notopterygii rhizoma alcohol with pharmaceutically acceptable adjuvants to obtain powder, unguent, powder, injection, aqua, enteric-coated sustained release preparation or injection. Animal experiments prove that the notopterygium alcohol can reduce OARSI scores, synovial membrane areas and cartilage defects of osteoarthritis mice, and reduce knee joint tissue damage and swelling of the osteoarthritis mice. The invention also discloses application of the notopterygium alcohol in preparing a medicament or a health-care product for treating osteoarthritis.
Description
Technical Field
The invention relates to a small molecular compound for treating osteoarthritis, and provides application of the small molecular compound in preparation of various forms of medicines or health-care foods for preventing and treating osteoarthritis.
Background
Osteoarthritis (OA) is a chronic degenerative disease of load-bearing joints, which is a common clinical disease of total joint diseases with progressive articular cartilage degeneration, narrow gap, synovial inflammation hyperplasia, subchondral bone remodeling as main pathological changes, and pain, swelling and joint deformity as main clinical manifestations. OA articular cartilage degeneration is irreversible, and an effective therapeutic drug is still lacked at present, so that the tibial high osteotomy and the joint replacement surgery are currently well-recognized effective therapies for treating KOA. While risk factors such as biomechanics, metabolism and genetics have been discovered, the exact pathogenesis of KOA remains unclear and the search for preventive and therapeutic KOA targets is a very popular area of research.
In recent years, our studies have confirmed that lymphatic return function plays an important role in the development and progression of osteoarthritis. When inflammation stimulates the proliferation of lymphatic vessels in tissues around joints and local transport lymph nodes, the inflammation also causes structural and functional abnormalities of collective lymphatic vessels, and leads to lymphatic return dysfunction around joints, further aggravating the symptoms of osteoarthritis. The idea of lymphatic return dysfunction in the inflammatory state, promoting lymphatic return and relieving osteoarthritis is consistent with the idea of pain caused by obstruction of arthralgia syndrome in traditional Chinese medicine and pain caused by obstruction of collaterals. The notopterygium alcohol researched by the invention can improve the lymphatic return function of osteoarthritis joints, reduce OARSI scores, synovial membrane areas and cartilage defects of osteoarthritis mice, and relieve tissue damage and swelling, thereby relieving osteoarthritis.
Disclosure of Invention
In view of the above-mentioned deficiencies of the prior art, according to the embodiments of the present invention, it is desirable to provide a small molecule compound for treating osteoarthritis with a definite therapeutic effect, and to propose a medical use thereof.
According to the embodiment, the small molecular compound for treating osteoarthritis provided by the technical scheme of the invention comprises the effective component of notopterygium alcohol, and the concentration of the notopterygium alcohol is 5-25 mu M. The notopterygium alcohol is an effective component extracted from dried root and rhizome of traditional Chinese medicine notopterygium, and can improve lymphatic return function of osteoarthritis joints, reduce OARSI score, synovial membrane area and cartilage defect of osteoarthritis mice, and relieve tissue injury and swelling, thereby relieving osteoarthritis.
According to the embodiment, the technical scheme of the invention is based on the effect of notopterygium alcohol as a medicament for treating osteoarthritis.
According to one embodiment, the invention proposes a medicament based on notopterygium alcohol as a therapeutic agent for osteoarthritis, the effective concentration of which is 5-25 μ M.
According to one embodiment, in the technical scheme of the invention, the notopterygium alcohol is mixed with pharmaceutically acceptable pharmaceutical excipients to form powder, paste, powder, injection, aqueous solution or injection.
According to one embodiment, the notopterygium alcohol as a therapeutic agent for osteoarthritis is prepared as a main active ingredient in various forms of drugs or health foods, which can be used for the prevention and treatment of the osteoarthritis. When in use, subcutaneous, intravenous injection or anorectal administration can be adopted; the injection can be selected from normal saline, glucose, stabilizer, antiseptic, suspending agent or emulsifier.
The invention carries out animal experiments, 40 clean grade 3-month-old C57BL male mice are randomly divided into a Sham group (Sham group), a KOA group (osteoarthritis group), a positive control group and a notopterygium alcohol group (the latter is the drug of the invention and is also called a treatment group) according to the weight, the notopterygium alcohol group is intragastrically filled with notopterygium alcohol every day, the SHAM group and the KOA group are intragastrically filled with physiological saline with the same amount every day, and the positive control group is intragastrically filled with Mobi every day. The result of the histomorphometry analysis of animal experiments shows that the notopterygium alcohol can reduce OARSI score, synovial membrane area and cartilage defect of a mouse with osteoarthritis, and reduce tissue damage and swelling, thereby reducing the osteoarthritis. Therefore, various forms of drugs or health foods prepared with notopterygium alcohol as a main active ingredient can be used for preventing and treating the osteoarthritis.
Drawings
FIG. 1 shows a structural formula of Notopterygii rhizoma alcohol.
FIG. 2 is a graph showing the results of ABOG staining of knee joints in animal in vivo experiments.
FIG. 3 is a diagram showing the results of testing the reflux function of joint lymph in an animal body experiment.
FIG. 4 is a diagram showing the results of ultrasonic testing of synovial fluid in animal body.
FIG. 5 is a diagram showing the results of the COLII immunohistochemical staining assay for knee joint in animal experiments.
FIG. 6 is a graph showing the results of immunohistochemical staining detection of MMP13 in knee joints in animal experiments.
FIG. 7 is a graph showing the results of immunofluorescence staining of synovial lymph vessels of knee joints in animal in vivo experiments.
FIG. 8 is a graph showing the results of the assay of Notopterygii rhizoma alcohol for reducing the expression of mRNA of lymphatic endothelial cell inflammatory factor in vitro.
Detailed Description
The invention is further illustrated with reference to the following figures and specific examples. These examples are to be construed as merely illustrative and not limitative of the remainder of the disclosure in any way whatsoever. After reading the description of the invention, one skilled in the art can make various changes and modifications to the invention, and such equivalent changes and modifications also fall into the scope of the invention defined by the claims.
In the following examples of the present invention, notopterygium alcohol (shown in figure 1 in simplified structure) is extracted from the dried root and rhizome of Notopterygium incisum by commercially available methods or extraction methods commonly used in the field of Chinese medicine. M is a molar concentration, namely mol/L; μ M is micromoles per liter.
Examples of the experiments
Dividing 40 clean-grade 3-month-old C57BL male mice into Sham group, KOA group, positive control group and Notopterygii rhizoma alcohol group at random according to body weight, wherein the Notopterygii rhizoma alcohol group is intragastrically administered at 10mg/kg/d of Notopterygii rhizoma alcohol per day, the SHAM group and KOA group are intragastrically administered with equal amount of physiological saline per day, and the positive control group is intragastrically administered at Mobi per day. After 12 weeks of continuous gavage treatment, the swelling degree of the knee joint and the reflux function of the joint lymph are detected, then the knee joint is taken, a paraffin specimen is prepared, a 4-micron continuous section is taken, the conditions of tissue injury, synovium hyperplasia and joint cartilage damage are observed by carrying out Alcinia and orange G (ABOG) staining, and the cartilage COLII and MMP13 and the number of lymphatic vessels are observed by immunohistochemistry and immunofluorescence staining.
4.1 mouse Joint specimen ABOG staining detection
Fixing mouse knee joint with 4% paraformaldehyde for 24h after taking materials, decalcifying for 18 days after soaking and cleaning with PBS, changing decalcifying liquid every 2-3 days, soaking and cleaning with PBS, dehydrating for 18h in a tissue dehydrator, soaking and embedding in paraffin in a paraffin embedding machine, slicing (4 μm) in sagittal position, horizontally placing glass slide in a baking sheet machine for 5h for pasting, vertically placing in a 60 ℃ oven for 8h for wax flowing, and then dewaxing to water in a ventilation cabinet by a conventional method; 1% hydrochloric acid ethanol for 30 sec; performing Alsinoblue staining for 40min in hematoxylin staining solution (AB); washing with water for 3 times; differentiating with 1% ethanol hydrochloride for 3 sec; washing for three times; 2% ammonia water rewet for 15 sec; washing with water for 3 times; 95% ethanol for 2 min; soaking in orange red dye liquor (OG) for 2min30 sec; 95% ethanol for 2 min; absolute ethyl alcohol for 5 min; xylene 5minX 3; a neutral gum sealing sheet, which is placed on the paperboard; placing in a fume hood for 3-4h to volatilize the residual xylene; drying in an oven at 60 deg.C for 2 h; VS120 full slice scanner scan.
As shown in FIG. 2, Elsinoblue blue stained articular cartilage, and intact blue stained ankle cartilage was observed in SHAM mice. However, in the knee ankle joint of the KOA mouse, blue-stained cartilage was significantly damaged and the joint structure was destroyed. Notopterygium koreanum group had significantly reduced articular cartilage destruction compared to the KOA group. The area of articular cartilage was measured, showing that notopterygium alcohol significantly reduced cartilage defects in osteoarthritis. In the knee joint of the SHAM mouse, the blue articular cartilage is flat and full, and in the knee joint of the KOA mouse, more severe cartilage loss and synovitis occur. Notopterygium forbesii alcohol group has significantly reduced cartilage damage compared with KOA group. The research result of the notopterygium alcohol suggests that the notopterygium alcohol can reduce the inflammation degree of osteoarthritis.
4.2 near-infrared-indocyanine green imaging detection mouse knee joint lymphatic return function
Starting a Matrx anesthesia machine, putting a mouse into an anesthesia box, performing isoflurane inhalation anesthesia (the concentration is 1% -1.5%), putting the mouse on a constant-temperature heating plate (28 ℃), maintaining anesthesia of a mask, conventionally preparing skin by using a depilatory cream, and wiping the depilatory cream with warm water to protect the skin of the mouse; ICG dye (0.1. mu.g/mL ICG solution prepared in advance with distilled water and stored in the dark) extracted by a 30-gauge needle micro-syringe was injected into the mouse in the knee joint cavity, and the injection time was recorded. Strong light signals of the knee joint can be observed under near-infrared irradiation, and photographs of the knee joint are taken 3 hours and 6 hours after injection respectively; the ICG signal intensity of the region of interest of the knee joint in the photograph can be obtained by analyzing the ROI (region of interest) region with Image J software (National Institutes of Health). The Clearance (clearence) of lymphatic vessels around the knee joint was calculated from the signal intensity of ICG in photographs taken at two time points of the knee joint on one side of the same mouse, and it can represent the lymphatic return function in the knee joint cavity. As shown in figure 3, the clearance rate of indocyanine green in the joints of the Sham group is the highest, the clearance rate of the joints of the KOA group is reduced, and the clearance rate of the notopterygium alcohol group is obviously improved. The results suggest that notopterygium alcohol reduces osteoarthritis by promoting OA-joint lymphatic return function.
4.3 ultrasonic detection of synovial fluid volume of knee joint of mouse by using small animal
Starting a Matrx anesthesia machine, putting a mouse into an anesthesia box, performing isoflurane inhalation anesthesia (the concentration is 1% -1.5%), putting the mouse on a constant-temperature heating plate (28 ℃), maintaining anesthesia of a mask, conventionally preparing skin by using a depilatory cream, and wiping the depilatory cream with warm water to protect the skin of the mouse; the knee joint of the mouse is placed under a probe of vevo2100 animal ultrasound, the scanning of the knee joint fluid volume is completed through B-mode and 3D-mode, and 3D reconstruction is completed through the software of the mouse. As shown in fig. 4, the amount of synovial fluid in the KOA group was significantly increased compared to the Sham group, and the amount of synovial fluid in the KOA group was significantly decreased by the notopterol group. The results suggest that the notopterygium alcohol can relieve osteoarthritis by promoting the OA joint lymph reflux function, and the notopterygium alcohol is a medicine for preventing and treating osteoarthritis.
4.4 mouse Joint specimen COLII immunohistochemical detection of cartilage degeneration
Dewaxing the paraffin tissue section to water conventionally, and washing for 3 times; absorbing water drops around the tissues by dust-free paper, assembling a pen drawing ring and putting the pen drawing ring into a wet box; dropwise adding 3% hydrogen peroxide, and keeping the temperature for 10 min; washing with water for 3 times, and dropwise adding trypsin for repairing at 37 deg.C for 10 min; washing with water for 3 times, and blocking with 4% BSA/PBS solution for 1 h; adding primary anti-dilution solution (anti-Collagen II, 1:1000 ratio, 0.4% BSA/PBS solution dilution) dropwise and incubating overnight in a refrigerator at 4 ℃; washing with PBS for 3 times, and soaking in PBS for 30 min; a second antibody, Goat Anti-Rabbit (diluted by 0.4% BSA/PBS solution at a ratio of 1: 200) is prepared at room temperature for 30min, and meanwhile, A + B diluent is prepared (diluted by two drops of A + two drops of B +5ml of 0.4% BSA/PBS solution at room temperature for 30 min); washing with PBS for 3 times, adding dropwise A + B mixed diluent, and standing at room temperature for 30 min; adding DAB color-developing agent for 3min (two drops of Buffer + two drops of H2O2 + four drops of DAB +5ml of distilled water, shaking and mixing uniformly, and using the mixture as ready; washing with water for 3 times, and dyeing with hematoxylin for 1min for 30 sec; washing with water for 3 times, and returning 2% ammonia water to blue for 15 sec; washing with water for 3 times, and dehydrating to obtain xylene; sealing neutral gum into a sheet; placing in a fume hood for 3-4h, and oven drying at 60 deg.C; VS120 full slice scanner scan. As shown in FIG. 5, COLII expression in the articular cartilage of the KOA group was significantly reduced compared to that of the Sham group, and the effect of COLII expression in the articular cartilage of the KOA group was significantly increased by using the notopterol group.
4.5 mouse Joint specimen MMP13 immunohistochemical detection of cartilage degeneration
Dewaxing the paraffin tissue section to water conventionally, and washing for 3 times; absorbing water drops around the tissues by dust-free paper, assembling a pen drawing ring and putting the pen drawing ring into a wet box; dropwise adding 3% hydrogen peroxide, and keeping the temperature for 10 min; washing with water for 3 times, and dropwise adding trypsin for repairing at 37 deg.C for 10 min; washing with water for 3 times, and blocking with 4% BSA/PBS solution for 1 h; adding primary anti-dilution solution (anti-Collagen II, 1:1000 ratio, 0.4% BSA/PBS solution dilution) dropwise and incubating overnight in a refrigerator at 4 ℃; washing with PBS for 3 times, and soaking in PBS for 30 min; a second antibody, Goat Anti-Rabbit (diluted by 0.4% BSA/PBS solution at a ratio of 1: 200) is prepared at room temperature for 30min, and meanwhile, A + B diluent is prepared (diluted by two drops of A + two drops of B +5ml of 0.4% BSA/PBS solution at room temperature for 30 min); washing with PBS for 3 times, adding dropwise A + B mixed diluent, and standing at room temperature for 30 min; adding DAB color-developing agent for 3min (two drops of Buffer + two drops of H2O2 + four drops of DAB +5ml of distilled water, shaking and mixing uniformly, and using the mixture as ready; washing with water for 3 times, and dyeing with hematoxylin for 1min for 30 sec; washing with water for 3 times, and returning 2% ammonia water to blue for 15 sec; washing with water for 3 times, and dehydrating to obtain xylene; sealing neutral gum into a sheet; placing in a fume hood for 3-4h, and oven drying at 60 deg.C; VS120 full slice scanner scan. As shown in fig. 6, the MMP13 of the articular cartilage of the KOA group was significantly increased compared to that of the Sham group, and the notopterol group significantly reduced the expression of MMP13 of the articular cartilage of the KOA group.
4.6 mouse Joint specimen PDPN/SMA immunofluorescence detection of lymphatic vessel number
Dewaxing the paraffin sections to water conventionally, and washing for 3 times; absorbing water drops around the tissues by dust-free paper, assembling pen-drawing rings and putting the pen-drawing rings into a wet box (a small amount of PBS can be dripped to prevent the specimens from being dried); adding trypsin dropwise, placing in a 37 ℃ thermostat, and repairing for 15 min; discarding trypsin, washing with water for three times, adding 4% BSA/PBS solution, and sealing at room temperature for 1 h; discarding the blocking solution, not washing, adding a mixed solution of primary anti-FITC alpha-SMA antibody (diluted by 0.4% BSA/PBS solution at a ratio of 1: 1500) and Podoplanin antibody (diluted by 0.4% BSA/PBS solution at a ratio of 1: 1000), and placing in a refrigerator at 4 ℃ for incubation overnight in the dark; taking out the wet box from the refrigerator, re-warming for 30min at room temperature, removing the primary antibody, and soaking and washing with PBS for 20minX 3; adding a secondary antibody Goat anti-hamster podoplanin (the proportion is 1:400, and the secondary antibody is diluted by 0.4% BSA/PBS solution), and incubating for 1h in a dark place at 4 ℃; discarding the secondary antibody, and washing for 3 times by PBS; soaking in 4 deg.C precooled PBS, and sealing with fluorescent sealing agent; VS120 full-scan scanner (fluorescence mode) scan. As shown in FIG. 7, the number of synovial lymph vessels in the joint of the KOA group was significantly reduced compared to that of the Sham group, and the number of synovial lymph vessels in the joint of the KOA group was significantly increased by the notopterygium alcohol.
4.7 detection of mRNA expression of IL-1beta, TNF-alpha, iNOS by using notopterygium alcohol.
RNA extraction (Trizol method): washing a 6-hole plate by PBS, adding Trizol 1 ml/hole, repeatedly blowing, standing at room temperature for 5min to fully crack, transferring the lysate into a 1.5ml enzyme-free EP tube, and marking; adding 200 μ l chloroform, shaking thoroughly and mixing for 15sec, standing at room temperature for 3 min; centrifuging at 12000rpm at 4 deg.C for 15 min; after centrifugation, the solution was divided into three layers, 200. mu.l of the upper aqueous phase was taken to another 1.5ml of EP; adding 200 μ l isopropanol, mixing, and standing at room temperature for 10 min; centrifuging at 4 deg.C and 12000rpm for 15min, and discarding supernatant; adding 1ml of 75% ethanol, and suspending and precipitating; centrifuging at 4 deg.C and 7500rpm for 5min, discarding ethanol, and removing the residual supernatant with 20 μ l gun; drying at room temperature for 5 min; add 20. mu.l DEPC water to dissolve the RNA sample.
Reverse transcription: prepare 20 μ l reaction: 1.5ml of EP tube was placed on ice and formulated according to takara instructions: 5X PrimeScript 4. mu.l, Oligo dT Primer 1. mu.l, PrimeScript RT Enzyme Mix I1. mu.l, Random 6mers 1. mu.l, DEPC water + RNA sample 13. mu.l, the mixture was shaken well and mixed, and centrifuged. Reverse transcription was set for 15min at 37 ℃, 5sec at 85 ℃ and 4 ℃. The reverse transcribed cDNA sample was diluted 5-fold and ready for use.
And (3) PCR reaction: after the primers are centrifuged at high speed, corresponding DEPC water is added to prepare 100 mu M of concentration, then the primers are diluted to 10 mu M, and 20 mu l of PCR reaction system is prepared according to the takara specification: SYBR 10. mu.l, dd water 7. mu.l, cDNA 1. mu.l, upstream and downstream primers 1. mu.l each. 5min at 95 ℃, 30sec at 95 ℃ → 30sec at 58 ℃ → 40sec at 72 ℃, 30 cycles, 7min at 72 ℃ and 4 ℃ storage. The same sample is simultaneously used for beta-actin internal reference PCR reaction. After the reaction is finished, absolute quantitative analysis is automatically carried out by using Rotor Gene6.0 software, the result is calculated, and the ratio of the copy number of each gene contained in each sample body to the copy number of the beta-actin internal reference gene is compared. As shown in FIG. 8, Notopterygii rhizoma alcohol significantly reduced IL-1 beta-induced gene expression of IL-1, TNF and iNOS inflammatory factors in endothelial cells.
Claims (4)
1. A small molecular compound for treating osteoarthritis is characterized in that the small molecular compound is notopterygium alcohol, and the effective action concentration is 5-25 mu M.
2. The small molecule compound for treating osteoarthritis according to claim 1, wherein the small molecule compound is mixed with pharmaceutically acceptable pharmaceutical excipients to form powder, ointment, powder, injection, aqua, enteric sustained release preparation or injection.
3. Use of the small molecule compound for treating osteoarthritis according to claim 1 or 2 in preparation of a medicament or health product for preventing and treating osteoarthritis.
4. Use according to claim 3, wherein the effective concentration of notopterygium alcohol is 5-25 μ M.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910997792.7A CN112755020A (en) | 2019-10-21 | 2019-10-21 | Small molecule compound for treating osteoarthritis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910997792.7A CN112755020A (en) | 2019-10-21 | 2019-10-21 | Small molecule compound for treating osteoarthritis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112755020A true CN112755020A (en) | 2021-05-07 |
Family
ID=75691455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910997792.7A Pending CN112755020A (en) | 2019-10-21 | 2019-10-21 | Small molecule compound for treating osteoarthritis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112755020A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114159454A (en) * | 2021-12-16 | 2022-03-11 | 中国药科大学 | Traditional Chinese medicine composition for preventing and treating Alzheimer disease and/or osteoporosis, preparation method and application |
| CN115844876A (en) * | 2022-11-23 | 2023-03-28 | 中国药科大学 | Medicine for preventing and treating rheumatoid arthritis and/or osteoarthritis and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109091477A (en) * | 2017-06-21 | 2018-12-28 | 上海中医药大学附属龙华医院 | The small molecule compound and application thereof for treating rheumatoid arthritis |
-
2019
- 2019-10-21 CN CN201910997792.7A patent/CN112755020A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109091477A (en) * | 2017-06-21 | 2018-12-28 | 上海中医药大学附属龙华医院 | The small molecule compound and application thereof for treating rheumatoid arthritis |
Non-Patent Citations (1)
| Title |
|---|
| 章芬等: "膝骨性关节炎中IL-1的调控及其干预进展", 《福建中医药》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114159454A (en) * | 2021-12-16 | 2022-03-11 | 中国药科大学 | Traditional Chinese medicine composition for preventing and treating Alzheimer disease and/or osteoporosis, preparation method and application |
| CN115844876A (en) * | 2022-11-23 | 2023-03-28 | 中国药科大学 | Medicine for preventing and treating rheumatoid arthritis and/or osteoarthritis and application thereof |
| CN115844876B (en) * | 2022-11-23 | 2023-09-29 | 中国药科大学 | Medicine for preventing and treating rheumatoid arthritis and/or osteoarthritis and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kikuth et al. | Experimental studies on the therapy of schistosomiasis | |
| ES2266512T3 (en) | COMPOSITIONS TO INHIBIT ANGIOGENESIS. | |
| Qiu et al. | Mesenchymal stem cell-derived extracellular vesicles attenuate tPA-induced blood–brain barrier disruption in murine ischemic stroke models | |
| CN105998014B (en) | Application of harmine derivative in preparation of medicine for treating cystic echinococcosis | |
| CN112755020A (en) | Small molecule compound for treating osteoarthritis and application thereof | |
| CA3035675C (en) | Pharmaceutical composition containing mtor inhibitor for treating macular degeneration | |
| WO2013177927A1 (en) | Injection-use esomeprazole sodium lyophilized powder composition and preparation method therefor | |
| AU2016266439B2 (en) | Bisamide derivative of dicarboxylic acid as an agent for stimulating tissue regeneration and recovery of diminished tissue function | |
| CN113181177B (en) | Application of harmine derivative in preparation of medicine for treating or preventing cystic echinococcosis | |
| CN113521041A (en) | Application of musk ketone in preparing medicine for preventing and treating osteoarthritis | |
| Botezatu et al. | Hepatic cystic echinococcosis studied in a family group | |
| Rosenthal | Pathological and Experimental Studies of Boeck’s Sarcoid: 1. Report of a Case with Panarteritis, Periarteritis, Terminal-hypertension and Uremia, and the Reproduction of a Sarcoid-like Lesion in Guinea Pigs | |
| JP2019517506A (en) | Composition for the treatment of liver cancer comprising a blood vessel destroying agent | |
| CN107625781B (en) | Application of miRNA inhibitor in preparation of medicine for preventing and treating myocardial infarction | |
| CN117860678B (en) | Pharmaceutical composition for treating alcoholic fatty liver and preparation method thereof | |
| RU2784896C2 (en) | Medical use of anemoside b4 against acute gouty arthritis | |
| CN112438987A (en) | Small molecule compound for treating lymphedema and application thereof | |
| WO2024060359A1 (en) | Use of glycerophospholipid compound in prevention and treatment of hyperlipidemia, atherosclerosis, non-alcoholic fatty liver disease, and obesity | |
| CN114533726B (en) | Small molecule drug for inhibiting fibrosis and application thereof | |
| CN114560817B (en) | Small molecule drug for inhibiting fibrosis and application thereof | |
| CN115944738A (en) | Application of complement C3 cracking inhibitor in preparation of medicine for treating diabetic cardiomyopathy | |
| CN104434900B (en) | Applications of the LCA in treatment of arthritis disease or articular cartilage and the medicine of destruction of bone is prepared | |
| CN116159061A (en) | Application of pyruvate kinase M2 activator in preparation of medicines for preventing or treating heart failure | |
| CN118340761A (en) | Application of oroxylin A in preparation of pharmaceutical composition for delaying rheumatoid arthritis | |
| CN118045146A (en) | Bird's nest composition with effect of preventing and treating benign prostatic hyperplasia and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |